Raihan R. Mardliyyah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raihan R. Mardliyyah has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Nuril Farid Abshori
Professional Medical Doctor Program, Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University, Malang, Indonesia
2 shared publications Achmad Z Arif
Department of Internal Medicine, Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University Malang, Indonesia
1 shared publicationAchmad Z. Arif
Department of Internal Medicine, Karsa Husada General Hospital, Batu, Indonesia
1 shared publication- Iwal R Ahdi
Department of Internal Medicine, Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University Malang, Indonesia
1 shared publication Iwal R. Ahdi
Department of Internal Medicine, Karsa Husada General Hospital, Batu, Indonesia
1 shared publication- Muhammad Habiburrahman
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 20 (06) , 854-863
Neutrophil‑ and platelet‑to‑lymphocyte ratios in sepsis: mortality links in diabetic patients and hospital burden in acute kidney injury
Introduction: Timely identification of sepsis patients at elevated risk for in-hospital mortality or prolonged hospitalization remains a clinical imperative. This study aimed to assess the prognostic utility of two readily available hematological biomarkers, namely the neutrophil-to-lymphocyte count ratio (NLCR) and platelet-to-lymphocyte count ratio (PLCR), for their association with mortality and length of stay (LOS) among sepsis patients, including high-risk subgroups with acute kidney injury (AKI) or type 2 diabetes mellitus (T2DM). Methodology: This retrospective 1-year cohort study included 202 adult sepsis patients. NLCR and PLCR were derived from admission complete blood counts. Receiver operating characteristic (ROC) curve analysis was used to evaluate discriminative performance, with optimal thresholds determined using Youden’s index. Kaplan–Meier and log-rank tests assessed survival differences, while LOS comparisons were analyzed using Mann–Whitney and Chi-square tests. Results: NLCR demonstrated limited overall prognostic value for mortality (AUC 0.560; sensitivity 53.68%; specificity 63.55%) but showed improved discrimination in patients with T2DM (AUC 0.603). PLCR was not associated with mortality in any subgroup (AUCs: 0.438–0.539). Diabetic patients with low NLCR had significantly higher survival (62.4% vs. 32.8%; p = 0.039). No significant survival differences were observed in the overall or AKI cohorts. Both NLCR and PLCR had poor association with LOS (AUC < 0.55). However, AKI patients with elevated NLCR had significantly prolonged hospitalization (11.5 ± 4.9 vs. 7.83 ± 4.5 days; p = 0.039). PLCR was not significantly associated with LOS. Conclusions: NLCR may provide modest, preliminary prognostic value in specific sepsis subgroups, particularly those with T2DM or AKI, and may serve as a low-cost adjunct for early risk stratification.
- 30 June 2026
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 20 (06) , 854-863
Open AccessNeutrophil‑ and platelet‑to‑lymphocyte ratios in sepsis: mortality links in diabetic patients and hospital burden in acute kidney injury
Introduction: Timely identification of sepsis patients at elevated risk for in-hospital mortality or prolonged hospitalization remains a clinical imperative. This study aimed to assess the prognostic utility of two readily available hematological biomarkers, namely the neutrophil-to-lymphocyte count ratio (NLCR) and platelet-to-lymphocyte count ratio (PLCR), for their association with mortality and length of stay (LOS) among sepsis patients, including high-risk subgroups with acute kidney injury (AKI) or type 2 diabetes mellitus (T2DM). Methodology: This retrospective 1-year cohort study included 202 adult sepsis patients. NLCR and PLCR were derived from admission complete blood counts. Receiver operating characteristic (ROC) curve analysis was used to evaluate discriminative performance, with optimal thresholds determined using Youden’s index. Kaplan–Meier and log-rank tests assessed survival differences, while LOS comparisons were analyzed using Mann–Whitney and Chi-square tests. Results: NLCR demonstrated limited overall prognostic value for mortality (AUC 0.560; sensitivity 53.68%; specificity 63.55%) but showed improved discrimination in patients with T2DM (AUC 0.603). PLCR was not associated with mortality in any subgroup (AUCs: 0.438–0.539). Diabetic patients with low NLCR had significantly higher survival (62.4% vs. 32.8%; p = 0.039). No significant survival differences were observed in the overall or AKI cohorts. Both NLCR and PLCR had poor association with LOS (AUC < 0.55). However, AKI patients with elevated NLCR had significantly prolonged hospitalization (11.5 ± 4.9 vs. 7.83 ± 4.5 days; p = 0.039). PLCR was not significantly associated with LOS. Conclusions: NLCR may provide modest, preliminary prognostic value in specific sepsis subgroups, particularly those with T2DM or AKI, and may serve as a low-cost adjunct for early risk stratification.
- Open Access
- 3 September 2025
- Published by Narra Sains Indonesia in Narra Review
- Vol. 1 (2) , e10
Effectiveness of mesoporous silica nanoparticle as drug delivery agents for therapeutic improvement of hepatocellular carcinoma: A systematic review
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for approximately 75% of all liver cancer cases, and has the worst prognosis. Current therapies for HCC remain suboptimal, with sorafenib therapy only prolonging survival by 2–3 months, combination therapies often cause adverse events (AEs), and drug resistance remains a challenge. To address these issues, mesoporous silica nanoparticles (MSNs) have been investigated as potential drug delivery systems due to their high surface area, tunable pore size, and ability to enhance drug stability and release. The aim of this study was to explore the potential of MSN-based drug delivery systems for improving HCC therapy. This study employed a systematic review design with a computerized search of six databases up to June 15, 2023. Inclusion criteria were: (1) in vivo studies with mouse subjects, (2) subjects with HCC receiving therapy, (3) therapy conjugated with or coated by MSNs, and (4) evaluation of therapeutic effectiveness based on statistical outcomes. Exclusion criteria included irrelevant titles or abstracts, incomplete texts, and non-original research such as reviews, case reports, and conference abstracts. A total of 1,844 studies were screened, and eight studies met the eligibility criteria for analysis. The results indicated that MSN-based drug delivery systems significantly improved therapeutic outcomes in HCC-bearing mice by enhancing drug penetration, reducing tumor size, and minimizing systemic toxicity compared to conventional formulations. These findings suggest that MSNs hold promise as an advanced drug delivery platform for HCC therapy. However, further preclinical and clinical studies are required before translation into clinical practice.
- 3 September 2025
- Published by Narra Sains Indonesia in Narra Review
- Vol. 1 (2) , e10
Open AccessEffectiveness of mesoporous silica nanoparticle as drug delivery agents for therapeutic improvement of hepatocellular carcinoma: A systematic review
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for approximately 75% of all liver cancer cases, and has the worst prognosis. Current therapies for HCC remain suboptimal, with sorafenib therapy only prolonging survival by 2–3 months, combination therapies often cause adverse events (AEs), and drug resistance remains a challenge. To address these issues, mesoporous silica nanoparticles (MSNs) have been investigated as potential drug delivery systems due to their high surface area, tunable pore size, and ability to enhance drug stability and release. The aim of this study was to explore the potential of MSN-based drug delivery systems for improving HCC therapy. This study employed a systematic review design with a computerized search of six databases up to June 15, 2023. Inclusion criteria were: (1) in vivo studies with mouse subjects, (2) subjects with HCC receiving therapy, (3) therapy conjugated with or coated by MSNs, and (4) evaluation of therapeutic effectiveness based on statistical outcomes. Exclusion criteria included irrelevant titles or abstracts, incomplete texts, and non-original research such as reviews, case reports, and conference abstracts. A total of 1,844 studies were screened, and eight studies met the eligibility criteria for analysis. The results indicated that MSN-based drug delivery systems significantly improved therapeutic outcomes in HCC-bearing mice by enhancing drug penetration, reducing tumor size, and minimizing systemic toxicity compared to conventional formulations. These findings suggest that MSNs hold promise as an advanced drug delivery platform for HCC therapy. However, further preclinical and clinical studies are required before translation into clinical practice.